Keith Michael Gottesdiener - Feb 25, 2024 Form 4 Insider Report for Prime Medicine, Inc. (PRME)

Role: President and Chief Executive Officer, Director
Signature: /s/ Karen Brown, attorney-in-fact
Stock symbol: PRME
Transactions as of: Feb 25, 2024
Transactions value $: $0
Form type: 4
Date filed: 2/27/2024, 09:35 AM
Previous filing: Nov 14, 2023
Next filing: Jun 7, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PRME	Stock Option (right to buy)	Award	$0	+100K		$0.00	100K	Feb 25, 2024	Common Stock	100K	$8.32	Direct	F1

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 25, 2024, subject to the Reporting Person's continued service on each such vesting date. Not reported herein are performance-based options awarded to the Reporting Person on the same transaction date, which vest upon the achievement of certain performance criteria. As of the transaction date, the performance criteria for such performance-based options have not yet been satisfied.

Content

1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 25, 2024, subject to the Reporting Person's continued service on each such vesting date. Not reported herein are performance-based options awarded to the Reporting Person on the same transaction date, which vest upon the achievement of certain performance criteria. As of the transaction date, the performance criteria for such performance-based options have not yet been satisfied.

Remarks:

President and Chief Executive Officer